Pfiz­er re­files Seagen ac­qui­si­tion pa­per­work, deal still ex­pect­ed to close with­in the year

Pfiz­er’s de­ci­sion to re­file the pa­per­work for its $43 bil­lion ac­qui­si­tion of Seagen like­ly al­lows the drug­mak­er to pro­vide more in­for­ma­tion about the deal to the Fed­er­al Trade Com­mis­sion and avoid a cost­ly de­lay, ac­cord­ing to SVB Se­cu­ri­ties an­a­lysts.

Pfiz­er an­nounced plans to buy Seagen back in March, po­ten­tial­ly out­bid­ding Mer­ck and mak­ing one of the biggest phar­ma­ceu­ti­cal deals ever. The ac­qui­si­tion, how­ev­er, may now be up for scruti­ny as a pos­si­ble tar­get for the FTC fol­low­ing the reg­u­la­tor’s pur­suit of an an­titrust case against Am­gen’s $28 bil­lion ac­qui­si­tion of Hori­zon Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER